| |
| |
|
| Insider
Information: |
Goeddel David V |
| Relationship: |
10% Owner |
| City: |
So. San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
21,008,913 |
|
|
Indirect Shares
|
68,439,735 |
|
|
| Direct
Value |
$85,796,072 |
|
|
|
Indirect Value
|
$141,495,125 |
|
|
| Total
Shares |
89,448,648 |
|
|
| Total
Value |
$227,291,197 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
21
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
21
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-21.0
|
0.0
|
| Percentage
Gain/Loss : |
 -65.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2025-03-05 |
58,713,849 |
Premium* |
|
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TNYA |
Tenaya Therapeutics, Inc. |
|
– • • |
2025-03-05 |
4 |
B |
$0.70 |
$24,999,999 |
I/I |
35,714,284 |
49,313,559 |
0.01 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2024-04-05 |
4 |
A |
$0.00 |
$0 |
I/I |
1,000 |
1,000 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(21,874,413) |
0 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(134,180) |
0 |
0 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
|
– • • |
2024-02-12 |
4 |
B |
$4.50 |
$9,999,999 |
I/I |
2,222,222 |
13,599,275 |
0.01 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– • • |
2023-11-16 |
4 |
B |
$0.62 |
$907 |
D/D |
1,460 |
134,180 |
0.01 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– • • |
2023-11-16 |
4 |
B |
$0.62 |
$3,627 |
I/I |
5,840 |
949,862 |
0.01 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– • • |
2023-11-15 |
4 |
B |
$0.71 |
$11,880 |
I/I |
16,791 |
944,022 |
0.01 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– • • |
2023-11-15 |
4 |
B |
$0.71 |
$1,919 |
D/D |
2,720 |
132,720 |
0.01 |
% |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-03-10 |
4 |
B |
$2.60 |
$17,596 |
I/I |
6,779 |
11,377,053 |
2.17 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-02-08 |
4 |
B |
$2.60 |
$3,900,000 |
I/I |
1,500,000 |
11,370,274 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-31 |
4 |
B |
$5.00 |
$883,403 |
I/I |
176,730 |
927,231 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-30 |
4 |
B |
$5.00 |
$37,707 |
I/I |
7,542 |
750,501 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-23 |
4 |
B |
$5.00 |
$49,494 |
I/I |
9,900 |
742,959 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-20 |
4 |
B |
$5.00 |
$2,498 |
I/I |
500 |
733,059 |
2.17 |
% |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-01-19 |
4 |
B |
$2.50 |
$174,201 |
I/I |
69,739 |
9,870,274 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-19 |
4 |
B |
$5.00 |
$188,105 |
I/I |
37,639 |
732,559 |
2.25 |
% |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-01-18 |
4 |
B |
$2.52 |
$341,432 |
I/I |
135,688 |
9,800,535 |
2.25 |
- |
|
| TNYA |
Tenaya Therapeutics, Inc. |
Director |
– • • |
2023-01-17 |
4 |
B |
$2.49 |
$123,395 |
I/I |
49,463 |
9,664,847 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-12 |
4 |
B |
$4.95 |
$26,603 |
I/I |
5,378 |
694,920 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-11 |
4 |
B |
$4.76 |
$994,840 |
I/I |
209,000 |
689,542 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2023-01-10 |
4 |
B |
$4.84 |
$484,519 |
I/I |
100,070 |
480,542 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2022-12-12 |
4 |
B |
$4.98 |
$1,493 |
I/I |
300 |
380,472 |
2.17 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2022-11-22 |
4 |
B |
$5.00 |
$21,646 |
I/I |
4,330 |
380,172 |
2.17 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2022-11-21 |
4 |
B |
$5.00 |
$179,942 |
I/I |
35,997 |
375,842 |
2.25 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
